Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal
about
Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob miceReviewing the Effects of L-Leucine Supplementation in the Regulation of Food Intake, Energy Balance, and Glucose HomeostasisProtection against the Metabolic Syndrome by Guar Gum-Derived Short-Chain Fatty Acids Depends on Peroxisome Proliferator-Activated Receptor γ and Glucagon-Like Peptide-1Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequencesGLP-1 increases microvascular recruitment but not glucose uptake in human and rat skeletal muscle.Glucagon-like peptide-1 (GLP-1): a piece of the incretin puzzle.Glucagon-like peptide-1 and glucose-dependent insulinotropic peptide: effects alone and in combination on insulin secretion and glucose disappearance in mice.The human glucagon-like peptide-1 analogue liraglutide preserves pancreatic beta cells via regulation of cell kinetics and suppression of oxidative and endoplasmic reticulum stress in a mouse model of diabetes.Single dose GLP-1-Tf ameliorates myocardial ischemia/reperfusion injury.Glucagon-like peptide-1 synthetic analogs: new therapeutic agents for use in the treatment of diabetes mellitus.Glucagon-like peptide-1 receptor knockout mice are protected from high-fat diet-induced insulin resistanceBreakfast frequency and quality may affect glycemia and appetite in adults and children.Beta-cell deterioration--prospects for reversal or prevention.Defective insulin secretory response to intravenous glucose in C57Bl/6J compared to C57Bl/6N mice.Glucose metabolism and cardiac hypertrophyGlucose effectiveness in obese children: relation to degree of obesity and dysglycemia.A noncytolytic antibody-like extendin-4-IgG4 fusion protein as a long-acting potential anti-diabetic agent.Chronic administration of the glucagon-like peptide-1 analog, liraglutide, delays the onset of diabetes and lowers triglycerides in UCD-T2DM rats.Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes.Effects of increasing doses of glucagon-like peptide-1 on insulin-releasing phases during intravenous glucose administration in mice.Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetesThe GLP-1 system as a therapeutic target.Glucagon-like peptide 1 (GLP-1) and metabolic diseases.Increased Glucose-induced Secretion of Glucagon-like Peptide-1 in Mice Lacking the Carcinoembryonic Antigen-related Cell Adhesion Molecule 2 (CEACAM2).Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis.Insulin secretion-independent effects of GLP-1 on canine liver glucose metabolism do not involve portal vein GLP-1 receptors.Weight loss induced by Roux-en-Y gastric bypass but not laparoscopic adjustable gastric banding increases circulating bile acids.Exenatide can reduce glucose independent of islet hormones or gastric emptying.Effects of intraportal exenatide on hepatic glucose metabolism in the conscious dog.Targeting beta-cell mass in type 2 diabetes: promise and limitations of new drugs based on incretinsThe glucagon-like peptide-1 receptor regulates endogenous glucose production and muscle glucose uptake independent of its incretin action.FGF19 action in the brain induces insulin-independent glucose loweringIncretin levels and effect are markedly enhanced 1 month after Roux-en-Y gastric bypass surgery in obese patients with type 2 diabetes.Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons.GLP-1R responsiveness predicts individual gastric bypass efficacy on glucose tolerance in ratsCooperation between brain and islet in glucose homeostasis and diabetes.Metabolic therapy at the crossroad: how to optimize myocardial substrate utilization?Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.The structure and function of the glucagon-like peptide-1 receptor and its ligandsPharmacologic agents for type 2 diabetes therapy and regulation of adipogenesis.
P2860
Q24629441-6B48B365-AA8A-4173-917D-370E1DD724C3Q26852743-28ABB49C-5EC5-40C2-B12F-F17BFB7E3F06Q27321785-A282F653-2FAE-445C-A55C-95BC25B92E9EQ28306665-30F6F905-8386-4A03-A6D1-856AC878ECC6Q30418716-FC2FDE48-4E17-4C47-A71E-1DF9AD86C83EQ33367023-85B6DF70-2B15-4742-8CC3-258309FCF7CDQ33800196-2604D8E0-5D02-41A8-AE8C-3CA14E5D65E8Q33826388-352FA8C7-7303-4B42-BF69-57E8F481B81BQ33925948-DB97537B-3C2A-44BF-8247-2B7496FF8656Q34026346-BE164671-2CC2-4B86-8789-D3C1806AA1B0Q34157515-E0044909-9FC0-46FB-9243-32AD190B8BAFQ34402292-6A5955D9-1B9A-4B0C-B3C6-74F60969B93FQ34422778-EF5B8D1B-3E2D-47CA-93B2-1AA588CE7546Q34687550-F28C6FC8-55BD-4788-A56F-41A7354C993BQ34808553-EFF5A6EC-8F36-4709-91CF-93D32F561632Q35207924-56E73BB8-2623-487B-94A4-13AB0C72ADE1Q35643633-E8D38FAC-FFA9-45D0-9E32-E6128435A93BQ35757217-6907993B-8917-4BDC-AE97-5E9C5A269FC5Q35772029-8FE295A8-4A1A-4036-B03A-6CD440E2F01CQ35801801-1335FCFF-A12C-447E-B9B4-85B001772339Q36017369-129DB0DC-3D20-493F-9BF1-A86604E014D9Q36265221-49FA3127-F05B-499B-ADF4-4BBC6CDB5BB5Q36309183-F1A09B31-8799-43F0-BB00-23403E2DC022Q36442462-189ABA4A-244B-420F-B06D-0C68B89B2F01Q36465496-D28673DB-4B2F-46DD-B7AC-FEA1491FED30Q36731945-A068FFE2-8095-420F-94F5-E280F0CFD520Q36736464-FE4DC1BE-A599-4AAC-9D95-9CB9A668808FQ36846123-71E6A317-5E10-4866-B7EB-B39222C9BCD2Q37051107-5F664697-4EF4-4632-8FF5-980DC2BD9406Q37091579-0E880F7B-45F7-4920-9AFC-ACBD586043A0Q37125933-CCDDC093-B4F0-4563-8121-FAFCBCB21546Q37259301-0C2B52D3-5AC5-4F98-998F-7B722767A275Q37345249-CABEA7E1-CDAF-447B-BB58-41CC307F38B8Q37351161-4334B6C6-6712-4CCE-813B-64EDCA5FCB77Q37510130-9E616929-7B73-4976-AADA-A5192E55BB48Q37698362-C9660E67-5815-47D7-9FAA-6421E42BDA9BQ37704721-F793C90F-3CAF-434D-8DD6-D2AABACD9F66Q37847181-8347FE59-5D57-4D77-8D31-6695EB659CEFQ37939244-C8A3B489-D55B-449C-953A-054DEF630EA1Q38110890-18A8CB2F-7F72-4A80-A20F-A9A6FD2D7DF4
P2860
Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal
description
1994 nî lūn-bûn
@nan
1994 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1994 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1994年の論文
@ja
1994年論文
@yue
1994年論文
@zh-hant
1994年論文
@zh-hk
1994年論文
@zh-mo
1994年論文
@zh-tw
1994年论文
@wuu
name
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@ast
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@en
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@nl
type
label
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@ast
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@en
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@nl
prefLabel
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@ast
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@en
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@nl
P2093
P2860
P356
P1476
Glucagon-like peptide 1 enhanc ...... n-independent glucose disposal
@en
P2093
C R Leusner
D A D'Alessio
J W Ensinck
P2860
Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach.
Hyperglycemia inhibits glucose production in man independent of changes in glucoregulatory hormones.
P304
P356
10.1172/JCI117225
P407
P577
1994-05-01T00:00:00Z